Literature DB >> 23012446

Early neurological deterioration after subarachnoid haemorrhage: risk factors and impact on outcome.

Raimund Helbok1, Pedro Kurtz, Matthew Vibbert, Michael J Schmidt, Luis Fernandez, Hector Lantigua, Noeleen D Ostapkovich, Sander E Connolly, Kiwon Lee, Jan Claassen, Stephan A Mayer, Neeraj Badjatia.   

Abstract

BACKGROUND: Early neurological deterioration occurs frequently after subarachnoid haemorrhage (SAH). The impact on hospital course and outcome remains poorly defined.
METHODS: We identified risk factors for worsening on the Hunt-Hess grading scale within the first 24 h after admission in 609 consecutively admitted aneurysmal SAH patients. Admission risk factors and the impact of early worsening on outcome was evaluated using multivariable analysis adjusting for age, gender, admission clinical grade, admission year and procedure type. Outcome was evaluated at 12 months using the modified Rankin Scale (mRS).
RESULTS: 211 patients worsened within the first 24 h of admission (35%). In a multivariate adjusted model, early worsening was associated with older age (OR 1.02, 95% CI 1.001 to 1.03; p=0.04), the presence of intracerebral haematoma on initial CT scan (OR 2.0, 95% CI 1.2 to 3.5; p=0.01) and higher SAH and intraventricular haemorrhage sum scores (OR 1.05, 95% CI 1.03 to 1.08 and 1.1, 95% CI 1.01 to 1.2; p<0.001 and 0.03, respectively). Early worsening was associated with more hospital complications and prolonged length of hospital stay and was an independent predictor of death (OR 12.1, 95% CI 5.7 to 26.1; p<0.001) and death or moderate to severe disability (mRS 4-6, OR 8.4, 95% CI 4.9 to 14.5; p=0.01) at 1 year.
CONCLUSIONS: Early worsening after SAH occurs in 35% of patients, is predicted by clot burden and is associated with mortality and poor functional outcome at 1 year.

Entities:  

Mesh:

Year:  2012        PMID: 23012446      PMCID: PMC3582083          DOI: 10.1136/jnnp-2012-302804

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


Background

Subarachnoid haemorrhage (SAH) is associated with a high mortality and morbidity.1 The detrimental effect of medical complications in the first 2 weeks after haemorrhage on long term outcome has been extensively studied.2–5 Additional determinants of poor outcome after SAH include age, neurological state at presentation and large aneurysm size.1 After the initial neuronal damage caused by the haemorrhage, neurological decline is often observed. Clinical worsening may occur early (within the first 24 h of admission) or late in the course of the disease. Several factors have been associated with clinical deterioration, including aneurysm rebleeding, hydrocephalus, delayed cerebral ischaemia from vasospasm, and seizures.4 6–10 However, admission variables predicting early neurological decline have not been evaluated, and the impact of early worsening on hospital course and outcome received little attention as a prognostic variable after SAH. In this study we sought to identify predictors for early worsening after SAH and to determine the impact of worsening on outcome.

Methods

Patient population and clinical management

All SAH patients admitted to the Neurological Intensive Care Unit of Columbia University Medical Center between July 1996 and May 2009 were offered enrolment in the Columbia University SAH Outcomes Project (n=1227). Consent rate was 98%. The study was approved by the hospital's institutional review board, and in all cases written informed consent was obtained from the patient or a surrogate. The diagnosis of SAH was established by admission CT scan or by xanthochromia of the CSF if CT was not diagnostic. Patients with SAH due to trauma, arteriovenous malformation, vasculitis or other structural lesions (n=242), as well as those aged <18 years (n=6) or admitted >24 h after SAH onset (n=237) and those without recorded Hunt–Hess grades on admission and worst Hunt–Hess grade within the first 24 h (n=24) were excluded. Additionally, admission Hunt–Hess grade V patients were not included in the final analysis due to inability of further deterioration (n=109). Clinical management according to guidelines set forth by the American Heart Association has been described in detail previously.3 4 11 We record the day of aneurysmal SAH as ‘day 0’ in our database.

Clinical and radiographic variables, and hospital complications

We recorded baseline demographic data, social and past medical history, clinical features at SAH onset and admission CT scan, as described previously.3 4 12 13 Neurological and general medical condition on admission was evaluated with the Hunt–Hess scale12 and the physiological subscore of the Acute Physiology and Chronic Health Evaluation (APACHE)-2 scale.11 Hunt–Hess grades on admission and at 24 h were evaluated by the treating neurointensivist (JC, NB, KL, SAM) and recorded. Hospital complications were prospectively recorded according to standardised definitions, including fever (body temperature ≥38.3°C), anaemia treated with blood transfusion (haemoglobin <9.0 g/l), aneurysm rebleeding, brainstem herniation, cerebral infarction (from any cause), hydrocephalus treated with CSF diversion, hyperglycaemia (blood glucose >11 mmol/l), hyponatraemia (serum sodium ≤130 mmol/l), hypotension (systolic blood pressure <100 mm Hg) requiring pressors, sepsis, pneumonia, pulmonary oedema, seizures and delayed cerebral ischaemia (delayed neurological deterioration, cerebral infarction or both) due to vasospasm.2 14 15 The Bicaudate Index was used as an estimated measure for the development of hydrocephalus.

Early neurological deterioration

In every patient, admission Hunt–Hess grade and the worst Hunt–Hess grade within the first 24 h of admission were recorded. Early neurological deterioration was defined as any increase in Hunt–Hess scale within the first 24 h of admission, with grades I and II combined as a single group of good grade patients. Procedure or sedation related deterioration was not considered as ‘early neurological deterioration’. The second evaluation was done ‘sedation free’ so as to minimise the effect of sedation. If sedation was considered the culprit, then a higher score was not assigned. External ventricular drain (EVD) placement was immediately performed in symptomatic patients, even before aneurysm repair. In general, EVD was in place by the time of the second score. In patients with early neurological deterioration, hydrocephalus requiring EVD placement was performed in 27% (admission Hunt–Hess grades 1 and 2, n=24/90), 61% (admission Hunt–Hess grade 3, n=42/69) and 81% (Hunt–Hess grade 4, n=42/52). Predictors for early neurological deterioration included only variables obtained on admission (demographics, past medical history, neurological and clinical examination, laboratory analyses and radiographic findings).

Outcome variables

Survival and functional outcomes were assessed at discharge and at 3 and 12 months, using the modified Rankin Scale (mRS).16 Poor outcome was defined as death or moderate to severe disability (mRS 4–6) at 12 months. If a 12 month mRS was not performed, day 14 (or discharge) or 3 month evaluation was carried forward.

Statistical analysis

All statistical analyses were performed using SPSS 18 software (SPSS Inc, Chicago, Illinois, USA). Significance was judged at p<0.05. Candidate predictor variables for worsening and mortality were identified by χ2 or Fisher exact tests for categorical variables and the Mann–Whitney U or two tailed t tests for continuous variables (table 1). Normality was assessed using the Kolmogorov–Smirnov test. Among similar variables that were highly intercorrelated (ie, clinical scales), only the variable with the highest OR and smallest p value in the binary logistic regression analysis was used as a candidate variable in the final multivariate model. Independent predictors of early worsening, death at 12 months and death or severe disability at 12 months were identified with backward stepwise multiple logistic regression analysis. Factors that occurred at a frequency of <5% were excluded from the final model. To determine the relative contributions of the individual predictors, we used Bayesian information criterion and Akaike's information criterion of the entire model after individual removal of each significant predictor. Tests for interaction were performed for all variables entered into the multivariable models. When significant two way interactions were identified, we reanalysed the predictive value of each factor after stratifying the analysis between the two levels of the other factor.
Table 1

Admission factors in relation to neurological deterioration in the first 24 h (n=609)

Worse (n=211)Stable (n=398)p Value
Demographics
 Age (years)57 (16)52 (13)0.001
 Female154 (73)297 (75)0.6
 Body mass index (kg/m2)27 (6)27 (7)0.9
 White ethnicity99 (47)180 (45)0.7
Social and past medical history
 Hypertension118 (56)175 (43)0.004
 Diabetes mellitus17 (8)28 (7)0.3
 Previous stroke7 (3)7 (2)0.2
Admission neurological and clinical findings
 Hunt–Hess grade3 (2–3)3 (1–3)0.3
  1 and 2, alert and oriented90 (43)179 (45)
  3, lethargic69 (33)137 (34)
  4, stuporous52 (25)82 (21)
 Loss of consciousness92 (44)134 (34)0.01
 APACHE-2 physiological subscore*6 (4–9)5 (3–8)<0.001
 Body temperature (°C)98 (97–99)98 (97–99)0.8
 Systolic blood pressure (mm Hg)160 (138–180)156 (133–180)0.2
 Heart rate (bpm)82 (69–96)80 (68–90)0.3
 Respiratory rate (/min)18 (16–20)18 (16–20)0.1
 Serum sodium (mmol/l)139 (136–140)138 (136–140)0.9
 Serum glucose (mmol/l)146 (126–178)137 (118–166)0.003
 White blood cell count (×109/l)11.6 (8.8–14.5)10.8 (8.3–13.7)0.08
 Troponin (µg/l)†0.2 (0.02–0.5)0.1 (0.02–0.3)0.4
Admission radiographic findings
 Modified Fisher scale3 (2–4)3 (1–3)<0.001
  0, no blood1 (1)12 (3)
  1, focal or diffuse thin SAH42 (20)124 (32)
  2, focal or diffuse thin SAH with bilateral IVH16 (8)29 (7)
  3, focal or diffuse thick SAH95 (45)162 (41)
  4, focal or diffuse thick SAH with bilateral IVH57 (27)71 (18)
 SAH sum score*19 (14–24)15 (10–21)<0.001
 IVH sum score*2 (0–4)1 (0–3)0.005
 Bicaudate Index (mm)0.17 (0.13–0.22)0.16 (0.12–0.20)0.004
 Haematoma42 (20)43 (11)0.003
 Vasospasm on admission angiogram11 (5)18 (5)0.7
 Aneurysm size >10 mm54 (26)92 (23)0.4

Values are presented as mean (SD), median (IQR) or number (%).

*APACHE-2 physiological subscore is the sum of four physiological variables: arterio-alveolar gradient >125 mm Hg=3, HCO3 <20 mmol/l=2, glucose 9.9 mmol/l=2 and mean arterial pressure <70 or >130 mm Hg=1 (range 0–8); SAH sum score grades the amount of blood in 10 basal cisterns and fissures (0=no SAH, 1=small SAH, 2=moderate SAH, 3=completely filled with SAH) by adding each of the 10 individual cistern scores (range 0–30); IVH sum score grades the amount of blood in the right and left lateral, third and fourth ventricel (0=no blood, 1=sedimentation, 2=partly filled, 3=completely filled) by adding each of the four individual ventricel scores (range 0–12).

†Missing variables in 45%.

APACHE, Acute Physiology and Chronic Health Evaluation, ICH, intracerebral haemorrhage; IVH, intraventricular haemorrhage; SAH, subarachnoidal haemorrhage.

Admission factors in relation to neurological deterioration in the first 24 h (n=609) Values are presented as mean (SD), median (IQR) or number (%). *APACHE-2 physiological subscore is the sum of four physiological variables: arterio-alveolar gradient >125 mm Hg=3, HCO3 <20 mmol/l=2, glucose 9.9 mmol/l=2 and mean arterial pressure <70 or >130 mm Hg=1 (range 0–8); SAH sum score grades the amount of blood in 10 basal cisterns and fissures (0=no SAH, 1=small SAH, 2=moderate SAH, 3=completely filled with SAH) by adding each of the 10 individual cistern scores (range 0–30); IVH sum score grades the amount of blood in the right and left lateral, third and fourth ventricel (0=no blood, 1=sedimentation, 2=partly filled, 3=completely filled) by adding each of the four individual ventricel scores (range 0–12). †Missing variables in 45%. APACHE, Acute Physiology and Chronic Health Evaluation, ICH, intracerebral haemorrhage; IVH, intraventricular haemorrhage; SAH, subarachnoidal haemorrhage.

Results

Frequency of early neurological deterioration

Of the 609 patients eligible for analysis, early worsening occurred in 35% of patients (n=211), equally distributed in patients where aneurysm was coiled (34%) and clipped (35%). Aneurysm repair was performed on day 1 of admission (median, IQR 1–1). Early worsening occurred by one (58%; to Hunt–Hess grade 3, n=63; to Hunt–Hess grade 4, n=42; to Hunt–Hess grade 5, n=52), two (34%; to Hunt–Hess grade 4, n=17; to Hunt–Hess grade 5, n=27) or three (8%; to Hunt–Hess grade 5, n=10) Hunt–Hess categories.

Predictors of early neurological deterioration

Of the clinical and radiographic variables associated with worsening in the univariate analysis (table 1), older age, intracerebral haematoma on initial CT scan, higher SAH sum and intraventricular haemorrhage sum scores were independent predictors of worsening within the first 24 h (table 2), after adjusting for admission Hunt–Hess grade, gender, admission year and procedure type (surgical/endovascular treatment of ruptured aneurysms). No interactions were found between these predictors in this final model.
Table 2

Multivariate analysis predicting neurological deterioration in the first 24 h*

VariableOR95% CIp Value
Age1.021.001 to 1.030.04
Intracerebral haematoma on initial CT2.01.2 to 3.50.01
SAH sum score†1.051.03 to 1.08<0.001
IVH sum score†1.11.01 to 1.180.03

*Adjusted for gender, admission Hunt–Hess grade, admission year and surgical/endovascular treatment.

†SAH and IVH sum scores are as described in the legend to table 1.

IVH, intraventricular haemorrhage; SAH, subarachnoidal haemorrhage.

Multivariate analysis predicting neurological deterioration in the first 24 h* *Adjusted for gender, admission Hunt–Hess grade, admission year and surgical/endovascular treatment. SAH and IVH sum scores are as described in the legend to table 1. IVH, intraventricular haemorrhage; SAH, subarachnoidal haemorrhage.

Hospital complications

The rate of hospital complications was higher in patients with early neurological deterioration, as shown in table 3.
Table 3

Hospital complications and outcome in relation to neurological deterioration in the first 24 h (n=609)

Worse (n=211)Stable (n=398)p Value
Fever >38.3°C153 (73)184 (46)<0.001
Anaemia treated with blood transfusion114 (54)115 (29)<0.001
Aneurysm rebleeding35 (17)15 (4)<0.001
Herniation52 (25)18 (5)<0.001
Hydrocephalus treated with CSF diversion108 (51)104 (26)<0.001
Hyperglycaemia (>11 mmol/l)124 (59)171 (43)<0.001
Hyponatraemia (<130 mmol/l)36 (17)59 (15)0.477
Hypotension requiring vasopressors67 (32)65 (16)<0.001
Pneumonia82 (39)58 (15)<0.001
Pulmonary oedema68 (32)44 (11)<0.001
Seizure25 (12)15 (4)<0.001
Sepsis41 (19)31 (8)<0.001
Delayed cerebral ischaemia73 (35)61 (15)<0.001
ICU LOS13 (9–19)9 (7–12)<0.001
Hospital LOS20 (13–31)13 (11–19)<0.001

Values are presented as median (IQR) or number (%).

χ2, Fisher exact tests or Mann-Whitney U or two tailed t tests were used as appropriate.

ICU,  intensive care unit; LOS,  length of stay.

Hospital complications and outcome in relation to neurological deterioration in the first 24 h (n=609) Values are presented as median (IQR) or number (%). χ2, Fisher exact tests or Mann-Whitney U or two tailed t tests were used as appropriate. ICU,  intensive care unit; LOS,  length of stay.

Twelve month outcome

Twelve month outcome data are presented in figure 1, including 184 patients (30%) where mRS was carried forward. Mortality was higher in patients with early neurological deterioration (18%, n=38, compared with 1%, n=2, at 14 days, and 28%, n=60, compared with 3%, n=13, at 12 months, p<0.001, respectively). Good recovery at 1 year (mRS 0–3) was observed in 52% of patients with early neurological deterioration (n=110) compared with 88% without neurological decline in the first 24 h of admission (n=351, p<0.001). Of the variables associated with mortality and severe disability and mortality in univariate analysis, age, admission Hunt–Hess grade, inhospital hyperglycaemia and early neurological deterioration were independently associated with 12 month outcomes (variables that were forced in the model were gender, admission year and surgical/endovascular treatment) (table 4).
Figure 1

Outcome of patients with (A, n=211) and without (B n=398) early neurological deterioration using the modified Rankin Scale (mRS) at hospital discharge, and at 3 months and 12 months after subarachnoidal haemorrhage. Percentages of subjects in different mRS categories are shown, with grades 0–2 combined as a single group of patients. This figure is only reproduced in colour in the online version.

Table 4

Predictors of mortality or severe disability and of mortality 12 months after subarachnoidal haemorrhage*

Dead or severely disabled†Dead
VariableOR95% CIp ValueOR95% CIp Value
Age1.051.03 to 1.07<0.0011.051.02 to 1.07<0.001
Admission Hunt–Hess2.61.9 to 3.4<0.0012.31.6 to 3.3<0.001
Hyperglycaemia (>11 mmol/l)‡2.21.2 to 4.1<0.001
Neurological deterioration in first 24 h8.44.9 to 14.50.0112.15.7 to 26.1<0.001

*Adjusted for gender, admission year and surgical/endovascular treatment.

†Defined as modified Rankin Scale >3.

‡Hyperglycaemia (≥11 mmol/l) at any point during hospitalisation.

Predictors of mortality or severe disability and of mortality 12 months after subarachnoidal haemorrhage* *Adjusted for gender, admission year and surgical/endovascular treatment. †Defined as modified Rankin Scale >3. ‡Hyperglycaemia (≥11 mmol/l) at any point during hospitalisation. Outcome of patients with (A, n=211) and without (B n=398) early neurological deterioration using the modified Rankin Scale (mRS) at hospital discharge, and at 3 months and 12 months after subarachnoidal haemorrhage. Percentages of subjects in different mRS categories are shown, with grades 0–2 combined as a single group of patients. This figure is only reproduced in colour in the online version.

Discussion

We found that early neurological deterioration after SAH is a strong predictor of death and poor functional recovery at 1 year. Older age and overall clot burden on admission predicted clinical worsening. The most novel finding in this study is that the initial haemorrhage load is an independent predictor for early neurological deterioration after SAH, regardless of whether the blood is intraventricular, intracerebral or in the subarachnoid space. The association of clot burden and early neurological deterioration may be explained by the evolving mass effect with intracerebral haemorrhage or through the development of obstructive hydrocephalus in patients with intraventricular bleeding.17 Although we did not find an association between the Bicaudate Index on admission and neurological deterioration, patients may have developed hydrocephalus thereafter. One can only speculate why the amount of subarachnoid blood in direct contact with the brain predicts early neurological deterioration. It may be that the toxicity of blood drives early metabolic and electrical failure of brain cells. This concept of neurohaemoinflammation is based on mechanical, biochemical and molecular changes, eventually leading to oedema, neurovascular uncoupling, apopotosis and cell death.18 19 Carefully designed studies using multimodal neuromonitoring techniques (microdialysis, brain tissue oxygen and EEG monitoring) or neuroimaging modalities (MR, positron emission tomography, single photon emission computed tomography) may capture these early pathophysiological changes in brain metabolism and physiology. Given the observed association between clot burden and early worsening, another target for intervention may be found in decreasing haemorrhage related energy demand of the acutely injured brain after poor grade SAH by pharmacological measures or hypothermia. Although intraoperative hypothermia does not improve outcome during aneurysm clipping,20 21 early and more prolonged hypothermia may be beneficial as a means of reducing cerebral energy demand or the tissue inflammatory response. Another strategy to minimise the harmful effects of subarachnoid and intraventricular blood might include cisternal or ventricular lavage, kinetic therapy or other methods for promoting early blood clearance.22 Early evacuation of packed intraventricular haemorrhage in poor grade SAH patients, however, did not show a favourable outcome.23 There is some evidence that lumbar drainage of CSF decreases symptomatic vasospasm and improves outcome after SAH24 but larger randomised trials are needed to support this intervention. The prognostic value of early worsening for poor outcome at 12 months is similar to that of previously identified risk factors, such as age, admission Hunt–Hess, rebleeding and aneurysm size. The strong association between worsening and various hospital complications in our study may account in part for the association with poor outcome. Haemorrhage load and the presence of intraventricular blood after SAH have been associated with inhospital complications and increased mortality.3 6 25 The most common hospital complication among patients with early neurological deterioration was fever (72%), which is a frequent epiphenomenon in neurocritical care patients,26 and is associated with neurological deterioration and poor outcome.2 7 27 28 Prevention of fever after SAH is a widely accepted management strategy and may improve outcome.29 Fifty-five per cent of patients with early worsening developed hyperglycaemia during hospitalisation. Prevention of hyperglycaemia has previously been shown to improve outcome in surgical and medical patients,30 31 but more recent trials have challenged these findings,32 leading to controversy regarding the optimal range of serum glucose in critical care.32 33 In acutely brain injured patients, the detrimental effect of hyperglycaemia on hospital course and functional outcome has been well studied5 34 35 but tight glycaemic control (4.4–6.2 mmol/l) has recently been associated with brain metabolic distress,36 as brain tissue glucose is primarily regulated by systemic supply.37 Prolonged cerebral tissue hypoglycaemia is predictive for poor outcome,38 39 therefore arguing for a less restrictive target for systemic glycaemic control in acutely brain injured patients.40 Several potential weaknesses of this study deserve mention. The single centre design of our study limits the generalisability of our results. The major limitation of this study is that other factors, which potentially cause early neurological deterioration (seizures, stunned myocardium, fever, etc.) were not investigated as these data were not recorded in a time locked way in our database. Furthermore, our data provide no information on early worsening in Hunt–Hess grade V patients, as they were not included in our analysis. Patients may deteriorate prior to hospital admission and after the first 24 h, and our study provides no data on these events. Finally, we analysed only admission predictors of neurological worsening. Due to the complex nature of neurological injury in SAH, we found it impossible to reliably identify specific complications, such as intracranial hypertension, obstructive hydrocephalus, brainstem herniation, seizures, rebleeding or acute cerebral infarctions as the primary cause of early worsening in individual patients. Although we record these complications in our database, we also do not have information regarding the timing of these events. Moreover, the exact hour of SAH bleeding and the exact time of neurological deterioration after admission was not recorded prospectively, which could also have influenced our results. If a 12 month mRS was not performed, the day 14 (or discharge) or 3 month evaluation was carried forward. The model predicting 1 year outcome was recalculated without patients with missing 12 month evaluations (30%) and did not show a significant change in variables.

Conclusions

In conclusion, our findings indicate that early neurological deterioration is an important predictor of poor outcome after SAH. Carefully designed prospective studies are needed to understand the pathophysiology of this phenomenon. Medical therapies aimed at preventing early deterioration after SAH may improve outcome.
  40 in total

Review 1.  A critical appraisal of stroke evaluation and rating scales.

Authors:  P D Lyden; G T Lau
Journal:  Stroke       Date:  1991-11       Impact factor: 7.914

2.  Surgical risk as related to time of intervention in the repair of intracranial aneurysms.

Authors:  W E Hunt; R M Hess
Journal:  J Neurosurg       Date:  1968-01       Impact factor: 5.115

3.  The influence of cisternal and ventricular lavage on cerebral vasospasm in patients suffering from subarachnoid hemorrhage: analysis of effectiveness.

Authors:  Daniel Hänggi; Hans-Jakob Steiger
Journal:  Acta Neurochir Suppl       Date:  2011

4.  Achieving normothermia in patients with febrile subarachnoid hemorrhage: feasibility and safety of a novel intravascular cooling catheter.

Authors:  Neeraj Badjatia; Joan O'Donnell; John R Baker; David Huang; Cenk Ayata; David M Greer; Bob S Carter; Christopher S Ogilvy; Colin T McDonald
Journal:  Neurocrit Care       Date:  2004       Impact factor: 3.210

5.  The effect of insulin on in vivo cerebral glucose concentrations and rates of glucose transport/metabolism in humans.

Authors:  E R Seaquist; G S Damberg; I Tkac; R Gruetter
Journal:  Diabetes       Date:  2001-10       Impact factor: 9.461

6.  Marked reduction of cerebral vasospasm with lumbar drainage of cerebrospinal fluid after subarachnoid hemorrhage.

Authors:  Paul Klimo; John R W Kestle; Joel D MacDonald; Richard H Schmidt
Journal:  J Neurosurg       Date:  2004-02       Impact factor: 5.115

7.  Causes of acute deterioration in patients with a ruptured intracranial aneurysm. A prospective study with serial CT scanning.

Authors:  M Vermeulen; J van Gijn; A Hijdra; H van Crevel
Journal:  J Neurosurg       Date:  1984-05       Impact factor: 5.115

8.  Predictive factors for deterioration from hydrocephalus after subarachnoid hemorrhage.

Authors:  F H Vermeij; D Hasan; M Vermeulen; H L Tanghe; J van Gijn
Journal:  Neurology       Date:  1994-10       Impact factor: 9.910

9.  Impact of medical complications on outcome after subarachnoid hemorrhage.

Authors:  Katja E Wartenberg; J Michael Schmidt; Jan Claassen; Richard E Temes; Jennifer A Frontera; Noeleen Ostapkovich; Augusto Parra; E Sander Connolly; Stephan A Mayer
Journal:  Crit Care Med       Date:  2006-03       Impact factor: 7.598

10.  Inpatient hyperglycemia following aneurysmal subarachnoid hemorrhage: relation to cerebral metabolism and outcome.

Authors:  Florian Schlenk; Peter Vajkoczy; Asita Sarrafzadeh
Journal:  Neurocrit Care       Date:  2009-05-06       Impact factor: 3.210

View more
  19 in total

1.  Current Advances in the Use of Therapeutic Hypothermia.

Authors:  Neeraj Badjatia; Christopher J White; Abbot Laptook; Markus Föedisch
Journal:  Ther Hypothermia Temp Manag       Date:  2013-09       Impact factor: 1.286

Review 2.  The Subarachnoid Hemorrhage International Trialists (SAHIT) Repository: advancing clinical research in subarachnoid hemorrhage.

Authors:  Blessing N R Jaja; Daniel Attalla; R Loch Macdonald; Tom A Schweizer; Michael D Cusimano; Nima Etminan; Daniel Hanggi; David Hasan; S Claiborne Johnston; Peter Le Roux; Benjamin Lo; Ada Louffat-Olivares; Stephan Mayer; Andrew Molyneux; Adam Noble; Audrey Quinn; Thomas Schenk; Julian Spears; Jeffrey Singh; Michael Todd; James Torner; Ming Tseng; William van den Bergh; Mervyn D I Vergouwen; George K C Wong
Journal:  Neurocrit Care       Date:  2014-12       Impact factor: 3.210

3.  Computed tomography perfusion as a predictor of delayed cerebral ischemia and functional outcome in spontaneous subarachnoid hemorrhage: A single center experience.

Authors:  Isabel Fragata; Marta Alves; Ana Luísa Papoila; Ana Paiva Nunes; Patrícia Ferreira; Mariana Diogo; Nuno Canto-Moreira; Patrícia Canhão
Journal:  Neuroradiol J       Date:  2019-02-19

4.  Evolution of diffusion tensor imaging parameters after acute subarachnoid haemorrhage: a prospective cohort study.

Authors:  Isabel Fragata; Patrícia Canhão; Marta Alves; Ana Luísa Papoila; Nuno Canto-Moreira
Journal:  Neuroradiology       Date:  2016-12-27       Impact factor: 2.804

5.  Early predictors of prolonged stay in a critical care unit following aneurysmal subarachnoid hemorrhage.

Authors:  Christopher D Witiw; George M Ibrahim; Aria Fallah; R Loch Macdonald
Journal:  Neurocrit Care       Date:  2013-06       Impact factor: 3.210

6.  Automated Quantification of Reduced Sulcal Volume Identifies Early Brain Injury After Aneurysmal Subarachnoid Hemorrhage.

Authors:  Jane Y Yuan; Yasheng Chen; Atul Kumar; Zach Zlepper; Keshav Jayaraman; Wint Y Aung; Julian V Clarke; Michelle Allen; Umeshkumar Athiraman; Joshua Osbun; Gregory J Zipfel; Rajat Dhar
Journal:  Stroke       Date:  2021-02-16       Impact factor: 7.914

7.  Higher brain extracellular potassium is associated with brain metabolic distress and poor outcome after aneurysmal subarachnoid hemorrhage.

Authors:  Ana Patrícia Antunes; Alois Josef Schiefecker; Ronny Beer; Bettina Pfausler; Florian Sohm; Marlene Fischer; Anelia Dietmann; Peter Lackner; Werner Oskar Hackl; Jean-Pierre Ndayisaba; Claudius Thomé; Erich Schmutzhard; Raimund Helbok
Journal:  Crit Care       Date:  2014-06-11       Impact factor: 9.097

8.  Elevated Systemic IL-6 Levels in Patients with Aneurysmal Subarachnoid Hemorrhage Is an Unspecific Marker for Post-SAH Complications.

Authors:  Shafqat Rasul Chaudhry; Birgit Stoffel-Wagner; Thomas Mehari Kinfe; Erdem Güresir; Hartmut Vatter; Dirk Dietrich; Alf Lamprecht; Sajjad Muhammad
Journal:  Int J Mol Sci       Date:  2017-12-01       Impact factor: 5.923

9.  Early neurological deterioration during the acute phase as a predictor of long-term outcome after first-ever ischemic stroke.

Authors:  He-Hong Geng; Qiang Wang; Bo Li; Bin-Bin Cui; Yong-Ping Jin; Rong-Li Fu; Qing Zhang; Jing-Jie Wang; Pei-Xi Wang
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

10.  Neurosurgeon academic impact is associated with clinical outcomes after clipping of ruptured intracranial aneurysms.

Authors:  Naif M Alotaibi; George M Ibrahim; Justin Wang; Daipayan Guha; Muhammad Mamdani; Tom A Schweizer; R Loch Macdonald
Journal:  PLoS One       Date:  2017-07-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.